ChemicalBook > CAS DataBase List > Tuvirumab
Tuvirumab
- Product Name
- Tuvirumab
- CAS No.
- 138660-97-6
- Chemical Name
- Tuvirumab
- Synonyms
- Tuvirumab;Research Grade Tuvirumab;Research Grade Tuvirumab (DVV03001)
- CBNumber
- CB11402547
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Tuvirumab Chemical Properties,Usage,Production
Uses
Monoclonal antibody (antiviral).
in vivo
Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; iv; single dose) followed by intravenous wild-type HBV, the MS-2 strain, directs against the a determinant of HBV surface antigen delayed but does not prevent experimental infection of HBV and hepatitis in the chimpanzee[1].
Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee[1].
Tuvirumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Tuvirumab Suppliers
- Tel
- 010-56205725
- Fax
- 010-65763397
- waley188@sohu.com
- Country
- China
- ProdList
- 12335
- Advantage
- 58
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
138660-97-6, TuvirumabRelated Search:
Ontamalimab
reslizumab
Radretumab
Atinumab
Ocaratuzumab
Placulumab
Elipovimab
Crizanlizumab
Pidilizumab
Sugemalimab